DKK 325.9
Key Takeaways
Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of NOVO-B.CO is 478 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
